Document Detail

Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
MedLine Citation:
PMID:  18445614     Owner:  NLM     Status:  MEDLINE    
Studies have shown conflicting results for glycoprotein IIb/IIIa inhibitor (tirofiban) use in ST-segment elevation myocardial infarction (STEMI). The authors aimed to determine if an upstream conventional dose of tirofiban in addition to a standard treatment regimen improved coronary patency and clinical outcomes in patients with STEMI. A retrospective analysis of consecutive patients with STEMI, who underwent emergent percutaneous coronary intervention (PCI) in the authors' hospital from July 2000 to April 2006 was performed. All patients received loading doses of aspirin, clopidogrel or ticlopidine, and unfractionated heparin with or without tirofiban in the emergency department prior to PCI. It was found that adding a conventional dose of tirofiban to the standard treatment regimen prior to PCI did not improve coronary patency in STEMI patients. Tirofiban also failed to show favorable outcomes for 90 days of follow-up, but there was a favorable trend for short-term 30-day survival.
Ching-Chang Fang; Yeun Tarl Fresner Ng Jao; Yi Chen; Ching-Lung Yu; Shih-Pu Wang
Related Documents :
25020794 - P410the impact of ischaemia reperfusion on aging rat heart physiological and molecular ...
24336014 - Heart failure and loss of metabolic control.
24465324 - Correction: igf signaling is required for cardiomyocyte proliferation during zebrafish ...
23722244 - Sum of effects of myocardial ischemia followed by electrically induced tachycardia on m...
15232124 - Population-based study of symptomatic internal carotid artery occlusion: incidence and ...
14739754 - The circadian variation of atrial defibrillation thresholds.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2008-04-29
Journal Detail:
Title:  Angiology     Volume:  60     ISSN:  1940-1574     ISO Abbreviation:  Angiology     Publication Date:    2009 Apr-May
Date Detail:
Created Date:  2009-04-20     Completed Date:  2009-05-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  192-200     Citation Subset:  IM    
Cardiovascular Center, Tainan Municipal Hospital, Tainan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Angiography
Dose-Response Relationship, Drug
Follow-Up Studies
Infusions, Intravenous
Middle Aged
Myocardial Infarction / mortality,  radiography,  therapy*
Platelet Aggregation Inhibitors / administration & dosage,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Retrospective Studies
Survival Rate
Taiwan / epidemiology
Treatment Outcome
Tyrosine / administration & dosage,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary collaterals in obese patients: impact of metabolic syndrome.
Next Document:  Analysis of left ventricular changes after acute myocardial infarction using transthoracic real-time...